Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allopurinol for cerebral and cardiac protection in neonates with critical congenital heart disease undergoing cardiopulmonary bypass
NL-OMON52736Phase 3Recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Cardiovascular Malformation (CVM) and traumatic brain injury (TBI) comparing Allopurinol with Placebo (2 arms). Primary endpoint: Primary composite outcome. Started Feb 2020; status: recruiting.
02
Drugs
allopurinol
03
Conditions
Cardiovascular Malformation (CVM)traumatic brain injury (TBI)
Beyond the preview
Go deeper on NL-OMON52736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52736.